1. Home
  2. TAK
  3. TAK News

Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) (TAK) News on July 27, 2024

TAK

MT Newswires

8 days ago

Dr. Reddy's Laboratories to Market Takeda's Acid-Reflux Medication in India

Shire Leasing accredited to deliver Growth Guarantee Scheme
TAK

Leasing Life

11 days ago

Shire Leasing accredited to deliver Growth Guarantee Scheme

Polpharma looks to challenge Takeda’s Entyvio in IBD
TAK

Pharmaceutical Technology

18 days ago

Polpharma looks to challenge Takeda’s Entyvio in IBD

TAK

MT Newswires

a month ago

Bloomberg Video: Takeda To Keep Pushing for China Biotech Partnership

Takeda Announces New Assignments of Directors
TAK

Business Wire

a month ago

Takeda Announces New Assignments of Directors

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
TAK

Zacks

a month ago

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

Takeda reports positive data from Phase IIb trial of ITP treatment
TAK

Clinical Trials Arena

a month ago

Takeda reports positive data from Phase IIb trial of ITP treatment

EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
TAK

Pharmaceutical Technology

a month ago

EC approves Takeda’s Fruzaqla for metastatic colorectal cancer

TAK

MT Newswires

a month ago

Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
TAK

Business Wire

a month ago

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
TAK

Business Wire

a month ago

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

TAK

MT Newswires

a month ago

Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
TAK

GlobeNewswire

a month ago

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
TAK

Business Wire

a month ago

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
TAK

CNW Group

a month ago

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older

Takeda reports long-term data from Phase III CIDP treatment trial
TAK

Clinical Trials Arena

a month ago

Takeda reports long-term data from Phase III CIDP treatment trial

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
TAK

Zacks

a month ago

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

TAK

MT Newswires

a month ago

Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK

Business Wire

a month ago

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Takeda’s epilepsy drug misses the mark in two Phase III trials
TAK

Clinical Trials Arena

a month ago

Takeda’s epilepsy drug misses the mark in two Phase III trials

TAK

MT Newswires

a month ago

Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall

Takeda drug for rare types of epilepsy misses goal in late-stage trial
TAK

BioPharma Dive

a month ago

Takeda drug for rare types of epilepsy misses goal in late-stage trial

TAK

MT Newswires

a month ago

Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK

Business Wire

a month ago

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda signs option agreement with Ascentage for CML drug
TAK

Pharmaceutical Technology

a month ago

Takeda signs option agreement with Ascentage for CML drug

TAK

MT Newswires

a month ago

Takeda Signs Option Agreement with Ascentage to License Leukemia Drug

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK

Business Wire

a month ago

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
TAK

BioPharma Dive

a month ago

Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
TAK

Business Wire

2 months ago

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
TAK

Simply Wall St.

2 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
TAK

AFP

2 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
TAK

Simply Wall St.

2 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
TAK

Simply Wall St.

2 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
TAK

Barrons.com

2 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
TAK

Simply Wall St.

2 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
TAK

Simply Wall St.

2 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?
TAK

Simply Wall St.

2 months ago

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints

TAK

MT Newswires

2 months ago

Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial

Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS
TAK

Clinical Trials Arena

2 months ago

Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK

Business Wire

2 months ago

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

Blackstone Is Considering the Sale of Alinamin Pharmaceutical, Sources Say
TAK

Bloomberg

2 months ago

Blackstone Is Considering the Sale of Alinamin Pharmaceutical, Sources Say

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
TAK

Business Wire

2 months ago

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK

Business Wire

2 months ago

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

TAK

MT Newswires

2 months ago

Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment

Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
TAK

CNW Group

2 months ago

Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection

Takeda’s dengue vaccine obtains WHO prequalification
TAK

Pharmaceutical Technology

2 months ago

Takeda’s dengue vaccine obtains WHO prequalification

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification

TAK

MT Newswires

2 months ago

Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute

TAK

MT Newswires

2 months ago

Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
TAK

Business Wire

2 months ago

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting

Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
TAK

Pharmaceutical Technology

2 months ago

Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy

Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
TAK

BioPharma Dive

2 months ago

Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
TAK

Business Wire

2 months ago

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

Catalyst's New CEO Has Big Ideas For The Small Biotech
TAK

Investor's Business Daily

3 months ago

Catalyst's New CEO Has Big Ideas For The Small Biotech

Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
TAK

Benzinga

3 months ago

Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%

Takeda tackles $900m restructuring plan after generics hurt annual profits
TAK

Pharmaceutical Technology

3 months ago

Takeda tackles $900m restructuring plan after generics hurt annual profits

Takeda targets ‘efficiency’ in restructuring, pipeline cuts
TAK

BioPharma Dive

3 months ago

Takeda targets ‘efficiency’ in restructuring, pipeline cuts

TAK

MT Newswires

3 months ago

Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
TAK

The Wall Street Journal

3 months ago

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK

Business Wire

3 months ago

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
TAK

GuruFocus.com

3 months ago

Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations

Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
TAK

Zacks

3 months ago

Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround

TAK

MT Newswires

3 months ago

European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer

Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
TAK

Zacks

3 months ago

Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
TAK

GlobeNewswire

3 months ago

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK

Business Wire

3 months ago

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
TAK

Zacks

3 months ago

All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy

TAK or CTLT: Which Is the Better Value Stock Right Now?
TAK

Zacks

3 months ago

TAK or CTLT: Which Is the Better Value Stock Right Now?

20 Fastest Growing Health Tech Companies in the World
TAK

Insider Monkey

3 months ago

20 Fastest Growing Health Tech Companies in the World

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
TAK

Zacks

3 months ago

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

New Strong Buy Stocks for April 25th
TAK

Zacks

3 months ago

New Strong Buy Stocks for April 25th

Best Value Stocks to Buy for April 25th
TAK

Zacks

3 months ago

Best Value Stocks to Buy for April 25th

Best Income Stocks to Buy for April 25th
TAK

Zacks

3 months ago

Best Income Stocks to Buy for April 25th

Takeda Pharmaceutical: A Long-Term Cash Cow
TAK

GuruFocus.com

3 months ago

Takeda Pharmaceutical: A Long-Term Cash Cow

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
TAK

PR Newswire

3 months ago

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Pharmas form joint venture to jumpstart Japanese drug research
TAK

BioPharma Dive

3 months ago

Pharmas form joint venture to jumpstart Japanese drug research

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
TAK

PR Newswire

3 months ago

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs

MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
TAK

Barrons.com

3 months ago

MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
TAK

Business Wire

3 months ago

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
TAK

Business Wire

4 months ago

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
TAK

Barrons.com

4 months ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK

PR Newswire

4 months ago

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
TAK

Business Wire

4 months ago

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK

Business Wire

4 months ago

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
TAK

Zacks

4 months ago

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
TAK

Business Wire

4 months ago

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
TAK

GlobeNewswire

4 months ago

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

Japan’s Stock Market Is Back, and It Isn’t Too Late to Buy
TAK

Barrons.com

4 months ago

Japan’s Stock Market Is Back, and It Isn’t Too Late to Buy

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
TAK

Business Wire

4 months ago

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
TAK

Zacks

5 months ago

Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?

TAK or STVN: Which Is the Better Value Stock Right Now?
TAK

Zacks

5 months ago

TAK or STVN: Which Is the Better Value Stock Right Now?

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
TAK

Zacks

5 months ago

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

Alexandria (ARE) Announces Lease Extension at Kendall Square
TAK

Zacks

5 months ago

Alexandria (ARE) Announces Lease Extension at Kendall Square

Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.
TAK

PR Newswire

5 months ago

Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
TAK

Business Wire

5 months ago

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Championing Rare Voices on Rare Disease Day
TAK

CNW Group

5 months ago

Championing Rare Voices on Rare Disease Day

Share on Social Networks: